Regulatory Authorities and Requests for Unblinded DMC Data and Reports
This article was originally published in SRA
There has been an increase in requests from regulatory authorities for unblinded DMC data and reports. Mats Ericson, Shamim Ruff, Alan Morrison, James Matcham and Steve Snapinn examine the issues and argue that such requests should as a matter of principle be challenged and preferably denied.
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.